Short answer
Aquestive Therapeutics, Inc. (AQST) filed an 8-K current report with the SEC on August 11, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results for quarter ended June 30, 2026.
Aquestive Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Business update included alongside reported results
- Detailed figures and financial schedules available in Exhibit 99.1
Item 7.01 · Regulation FD Disclosure
- Investor presentation furnished under Regulation FD for institutional and analyst meetings
- Exhibit 99.2 contains the substantive company information investors should review
- Presentation may be amended or updated through subsequent filings or other disclosures
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $13.8M, up 38% from $10.0M, driven by higher manufacturing, supply, license, and royalty revenue
- Anaphylm human-factors and PK studies completed; NDA resubmission remains targeted for Q3 2026 after January CRL
- FDA expedited review will be requested, but approval timing remains uncertain and Anaphylm launch depends on regulatory clearance
- Net loss $22.9M included an $11.7M one-time debt extinguishment loss; adjusted EBITDA loss improved to $5.2M from $9.3M
- Cash $98.5M; 2026 guidance unchanged at $46–$50M revenue and $35–$30M adjusted EBITDA loss
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aquestive Therapeutics, Inc. 8-K filings
Get the next AQST 8-K as it lands
Follow AQST for push alerts, or ask the research agent what this filing means.